Contents9 sections
Mod GRF 1-29 is a modified version of the first 29 amino acids of human growth hormone-releasing hormone (GHRH). The modification involves four amino acid substitutions that increase the peptide’s resistance to enzymatic degradation, extending its half-life from approximately 5 minutes (native GHRH) to roughly 30 minutes. This compound is also known as CJC-1295 without DAC (Drug Affinity Complex), and the two names are used interchangeably in the peptide community.
The Mod GRF 1-29 peptide works by binding to GHRH receptors on pituitary somatotroph cells, triggering a signaling cascade through cyclic AMP and protein kinase A that stimulates growth hormone synthesis and secretion. Unlike exogenous HGH, this process preserves the body’s natural pulsatile GH release pattern and maintains negative feedback regulation through somatostatin.
Key Takeaways
- Mod GRF 1-29 is identical to CJC-1295 without DAC — they are the same compound sold under different names.
- It stimulates natural growth hormone release from the pituitary gland through the GHRH receptor pathway.
- Standard dosage is 100 mcg per injection, administered 1-3 times daily via subcutaneous injection.
- Most commonly stacked with Ipamorelin for synergistic GH release through dual pathway activation.
- The compound does not suppress natural hormone production and does not require PCT.
What Is Mod GRF 1-29?
Mod GRF 1-29 consists of amino acids 1-29 of the 44-amino-acid human GHRH sequence, with four substitutions at positions 2, 8, 15, and 27. These modifications replace metabolically vulnerable amino acids with more stable alternatives, preventing rapid enzymatic breakdown that limits native GHRH’s effectiveness.
Quick Facts
| Property | Detail |
|---|---|
| Other names | CJC-1295 without DAC, Modified GRF (1-29) |
| Type | GHRH analog (growth hormone-releasing hormone) |
| Structure | 29 amino acids (modified) |
| Administration | Subcutaneous injection |
| Half-life | ~30 minutes |
| Standard dose | 100 mcg per injection |
| Mechanism | GHRH receptor agonist — stimulates pituitary GH release |
| PCT required | No |
How It Differs from CJC-1295 with DAC
The critical distinction is the DAC (Drug Affinity Complex). CJC-1295 with DAC binds to albumin in the bloodstream, extending its half-life to 6-8 days. This produces sustained, non-physiological GH elevation. Mod GRF 1-29 (without DAC) has a 30-minute half-life, producing short, pulsatile GH release that mimics the body’s natural secretion pattern.
For most users, the no-DAC version is preferred because pulsatile GH release preserves pituitary sensitivity and avoids the receptor desensitization that can occur with continuous GH stimulation.
Mod GRF 1-29 Benefits
Growth Hormone and IGF-1 Elevation
The primary Mod GRF 1-29 benefit is stimulating the pituitary to release GH in its natural pulsatile pattern. Research on GHRH analogs has demonstrated dose-dependent increases in GH and IGF-1 levels with sustained administration. Elevated GH and IGF-1 support protein synthesis, tissue repair, and metabolic function across multiple organ systems.
Muscle Recovery and Growth
Higher GH and IGF-1 levels support faster recovery between training sessions, improved nitrogen retention, and enhanced protein synthesis. While the Mod GRF 1-29 peptide is not anabolic in the same category as steroids or SARMs, it provides a GH-mediated foundation that supports muscle growth when combined with progressive resistance training and adequate nutrition.
Fat Loss
Growth hormone activates hormone-sensitive lipase in adipose tissue, mobilizing stored fat for energy use. The Mod GRF 1-29 benefits for fat loss are driven by this lipolytic effect, with preferential targeting of visceral fat. Users typically report improvements in body composition over 8-12 weeks of consistent use.
Sleep Quality and Recovery
GH is naturally released in its largest pulse during deep sleep. Administering Mod GRF 1-29 before bed amplifies this nocturnal GH surge. Improved sleep depth and quality is one of the earliest reported effects, often noticeable within the first 1-2 weeks. Better sleep cascades into improved recovery, cognitive function, and energy levels.
Skin and Anti-Aging
Elevated IGF-1 stimulates collagen synthesis and cellular renewal. Users frequently report improvements in skin elasticity, reduced fine lines, and improved hair and nail quality over 8-16 weeks of consistent use.
Mod GRF 1-29 Dosage
Standard Protocols
| Protocol | Dose | Frequency | Timing |
|---|---|---|---|
| Beginner | 100 mcg | 1x daily | Before bed |
| Standard | 100 mcg | 2x daily | Morning + before bed |
| Advanced | 100-200 mcg | 3x daily | Morning + post-workout + before bed |
Administration Guidelines
- Injection method: Standard subcutaneous injection into the abdomen or thigh. Rotate injection sites.
- Timing: Inject on an empty stomach (at least 2 hours after eating). Avoid eating for 30 minutes post-injection, as elevated blood glucose blunts the GH response.
- Reconstitution: Add bacteriostatic water to the lyophilized vial. Store reconstituted solution refrigerated and use within 21 days.
- Cycle length: 8-12 weeks on, 4-6 weeks off. Cycling prevents receptor desensitization and maintains response quality.
Stacking with Ipamorelin
The most effective use of Mod GRF 1-29 is in combination with Ipamorelin. This is the same compound pairing as the Ipamorelin + CJC-1295 stack (since Mod GRF 1-29 is CJC-1295 no DAC). The Mod GRF 1-29 dosage in this stack is typically 100 mcg alongside 200-300 mcg of Ipamorelin, both drawn into the same syringe and injected together.
The synergy works because the GHRH analog activates the GHRH pathway while Ipamorelin activates the ghrelin receptor pathway. These two mechanisms converge on the same pituitary cells, producing a greater GH response than either compound alone.
Mod GRF 1-29 Side Effects
The compound has a mild side effect profile because it works through the body’s existing GH signaling rather than introducing exogenous hormones.
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Injection site redness | Common | Standard for subcutaneous peptides; rotate sites |
| Water retention | Occasional | Mild puffiness in hands/feet; dose-dependent |
| Headache | Occasional | Usually transient; more common in first 1-2 weeks |
| Tingling/numbness | Uncommon | Paresthesia from elevated GH; reduce dose if persistent |
| Increased appetite | Rare | Less pronounced than with GHRP-2 or GHRP-6 |
Safety Considerations
- No HPTA suppression: Mod GRF 1-29 does not affect testosterone, estrogen, or the hypothalamic-pituitary-gonadal axis. PCT is not required.
- No cortisol or prolactin elevation: Unlike some GHRP compounds, this peptide does not significantly affect cortisol or prolactin levels.
- Blood glucose: Extended use of any GH-elevating compound may affect insulin sensitivity. Monitor fasting glucose during longer cycles.
- Cancer contraindication: Elevated GH/IGF-1 may theoretically stimulate growth in existing malignancies. Individuals with active cancer should not use GH secretagogues.
Mod GRF 1-29 vs Other GH Secretagogues
| Feature | Mod GRF 1-29 | CJC-1295 with DAC | Ipamorelin | Tesamorelin |
|---|---|---|---|---|
| Mechanism | GHRH receptor | GHRH receptor (albumin-bound) | Ghrelin receptor | GHRH receptor |
| Half-life | ~30 min | ~6-8 days | ~2 hours | ~26 min |
| GH release | Pulsatile | Sustained (non-physiological) | Pulsatile | Pulsatile |
| Dosing frequency | 1-3x daily | 1-2x weekly | 1-3x daily | 1x daily |
| Pituitary desensitization risk | Low | Higher (sustained stimulation) | Low | Low |
| Best used | As part of Ipamorelin stack | Solo or with GHRP | As part of Mod GRF stack | Solo for visceral fat |
| FDA status | Research chemical | Research chemical | Research chemical | FDA-approved (Egrifta) |
The compound is most effective when stacked with a ghrelin-pathway agonist (Ipamorelin being the standard choice). Used alone, it produces moderate GH elevation. The combination creates the dual-pathway synergy that makes the Ipamorelin + CJC-1295 no DAC stack the most widely used GH peptide protocol.
The Bottom Line
This GHRH analog is the standard GHRH-pathway component of the most popular GH peptide stack in use today.
- Its modified amino acid structure provides the stability needed for practical subcutaneous administration, while its short half-life preserves the pulsatile GH release pattern that keeps the pituitary responsive
- The Mod GRF 1-29 peptide offers a well-tolerated, PCT-free approach to GH optimization with documented benefits for body composition, recovery, sleep quality, and anti-aging.
- The compound is most effective when stacked with Ipamorelin to achieve dual-pathway GH stimulation.
Frequently Asked Questions
Disclaimer
Please read carefully
The information on this site is for educational and informational purposes only, and is not medical advice. Always consult a qualified healthcare professional before using any supplement or medication, or making changes to your health, fitness, or nutrition routine.
Not medical advice
Content here is not a substitute for professional medical advice.
Consult your doctor
Talk to your doctor before starting any supplement or new routine.
Use at your own risk
We are not responsible for adverse effects from acting on this.
Do your research
Make informed decisions about your own health.
No guarantees
Individual results vary. No claims about outcomes.
Important — Never disregard professional medical advice or delay seeking it because of something you read here. If you think you may have a medical emergency, call your doctor or your local emergency number right away.
